Member Info for Ghia

Nolupus - I wonder if the standard of care drugs will be different for the at home trials. I can find out what the standard of care drugs are in the hospital setting easy enough my brother in law is a senior pharmacist and posted a COVID-19 ward currently.

I'll ask him at let you know the response.

Nolupus - I remember Richard saying that we had an advantage because we where already in a trial we had Placebo lined up and ready to use.

Does the fact we have placebo mean that we are not measuring against standard of care?

I thought maybe wrongly that standard of care was used in the event that placebo was not available?

It's great having both trials being headed up Tom Wilkinson at Southampton. Would not be surprised if drug combinations are the only way out of this.

It just had a 10% intraday reversal

Nolupus - Continue to add to the narrative as you see fit and let people make up their own mind on the research put in front of them.

Personally your reference to AZN earlier just proved that large pharma has buckets of cash to chuck at drugs. The drug you mentioned failed phase 3 trials at first attempt so they had a second go and it passed. It also had the side effect of shingles in 1 in 14 patients that took the drug.

If you look at the big picture here AZN might have given back the rights for ASTHMA but this drug could now be much bigger than ASTHMA it is now a different proposition for them and they will have to pay a lot more because they didn't contribute to the funding.

Don't underestimate the lubricating effect of having contacts within an organisation already. As already said they will be familiar with the paperwork and documentation requirements, hopefully be on first name terms with the admin staff every little helps.

Safy - The news up until date has been informative and painting a picture of where the company is heading. The share price arrives at a level whereby people are happy with the risk reward the trading range 55-75 seems to suit all the factors currently in play, time to results, sellers, buyers etc.

The closer we get to June the trading range might change as the window of getting in before news closes.

Once we get an RNS with information on Licensing Agreements etc this will crystalise the value here and it will not matter where the share price started from.

I hate using NCYT as an example but they peaked at £5 on rumour and excitement they are now hovering round £4 off the back of several RNS's which have financial information in so the point i'm trying to make is the fair price will be found when all news is in play regardless of starting share price.

There is definitely less Hot Money bouncing around on the Covid Plays have the rainbow chasers lost it all already? What will they do for the rest of lockdown...

ShareSting - How does the saying go "you can lead a horse to water..." The longer we remain at these levels the more I top up so whilst frustrating for all involved i'm also not complaining too much.

Kwaboy - I think most agree that it is just the same trial logged with the American authorities.

This was also confirmed by Richard according to nobby on Advfn.

my Interpretation of that article is that not enough patients where experiencing severe exacerbation triggered by colds or flu. So the trial would not produce meaningful data because the placebo group was yielding incredibly strong response.

They canned the trial because no conclusions could be drawn from the interim data.

Since then we’ve had the COPD trial which was timed to coincide with virus seasons so was running for over a year.

I don’t think AZN previous experiences are a negative, if anything the current pandemic has highlighted that the market for a drug like this might be much larger than originally thought.

I may be wrong but nebulisation is just dispersing the drug into a mist.

You can breath the mist in via a tube at the mouth or using a mask over the mouth and nose.

Nasal drops would be completely different and something we do not have a patent over.

I suspect the breath in via nose text is just a red herring

A little above Thursdays less than the days that saw news land.

Spot on Chris. It was also posted on ADVFN by nobby that the 120 at home patients are part of the 400 total.

So 100 hospital, 120 at home leaving 280 contingency if required.

Johnht - You'd have to cross reference the trades with the spread from yesterday to try and work it out. I assume they are all sells by Lansdowne, these trades started to appear when they started offloading when they stop appearing I expect they will be done.

Dave - I don't think you can read too much into the dates on the trials register. They will be rough estimates better to stick to the RNS's and CEO interviews end of June is the most accurate statement we have to dat for Trial data.

CW25 - If interested 577,578 of volume appearing after hours again today delayed from yesterday.

Nolupus - 31/08/2020 Fantastic isn't it that we can get to this point so quickly normally these things takes years COPD was set to span several virus seasons.

"We may not have the silver bullet here but we will certainly know which of the studies showed the greatest promise and we can add other drugs to a cure."

This comment was directly after the section naming Inteferon Beta. It's the only trial directly referenced in the article.

"What we think, eventually for Covid-19, it may not be a single drug, there may be a combination needed to get the patient better."

Again this aligns with what the CEO said we may need a combination of treatments.

I'm certain our drug in it's inhaled form will be just that.

I got 1232 in total across 3 accounts:

ShareCentre Applied 20k got Zero They decided not to participate
HL My Account Applied 20k got 405
HL Wifes Account Applied 2. 5k got 827